The GCC pharmaceutical market exceeded $30 billion in 2025, according to a new JLL report, as Saudi Arabia and the UAE accelerated their investment in life sciences manufacturing, research infrastructure and healthcare delivery. That figure, significant in isolation, understates the trajectory. The life sciences sector across the Gulf is growing at rates that reflect a structural expansion of healthcare ambition, not just a cyclical uptick in pharma spending, and the UAE is positioning itself to capture a disproportionate share of the value being created as the sector scales.
The UAE’s life sciences strategy has several distinct components working in parallel. The manufacturing base, historically thin compared to the country’s healthcare consumption, is being expanded through incentives for pharmaceutical manufacturers to establish production facilities in UAE free zones, particularly in Abu Dhabi’s life sciences cluster and in Dubai Science Park. The clinical research infrastructure, which is necessary for the UAE to attract pharmaceutical companies seeking to run trials in a diverse, internationally mobile patient population, has been strengthened through regulatory reforms that make the UAE one of the faster approval environments in the region. And the healthcare delivery network, bolstered by significant public and private investment over the past decade, provides the clinical ecosystem into which new pharmaceutical products and medical technologies can be introduced and scaled.
“The GCC pharmaceutical market exceeded $30 billion in 2025, driven by rising healthcare expenditure, population growth and government-led investments in life sciences manufacturing and research. Saudi Arabia and the UAE are leading a structural expansion of the sector that is expected to accelerate through 2030.”
— JLL, GCC Life Sciences and Healthcare Investment Report 2026 (jll.com, July 2026)
What the UAE Is Building in Life Sciences Right Now
The most significant recent development in UAE life sciences is the Abu Dhabi Longevity Authority, established in June 2026 with Sheikh Hamdan bin Mohammed as its president. That institution, dedicated to positioning Abu Dhabi as a global hub for regulated longevity medicine, precision health and wellness, represents a category of healthcare investment that goes beyond treating illness and into the far larger market of optimising health and extending healthy lifespan. The global longevity economy is valued at approximately $17 trillion. The UAE has made a deliberate institutional bet that it can capture a meaningful share of that market by combining its healthcare infrastructure, its regulatory willingness to engage with novel longevity interventions, and its ability to attract the ultra-high-net-worth individuals who are the primary consumers of premium longevity services.
The Aldar-PureHealth partnership, announced in 2026, is embedding clinical preventive health infrastructure into Aldar’s residential communities at the master planning stage. SHA Wellness Clinic has established its first Middle East flagship in the UAE. And MBZUAI is building the AI models that will power the predictive health analytics underpinning the next generation of personalised medicine. These are not isolated initiatives. They are components of a connected life sciences strategy that spans real estate, clinical care, technology, regulatory affairs and consumer health, and that is being assembled with the institutional coordination that the UAE’s governance model enables.
Why This Matters for Businesses Across the UAE
The $30 billion GCC pharma market figure and the UAE’s growing life sciences ambition have implications that extend well beyond the healthcare sector. For real estate developers, the longevity and wellness infrastructure buildout creates demand for specialised clinic space, wellness residential communities and medical tourism accommodation. For technology companies, the digitisation of health records, the deployment of AI diagnostics and the management of precision medicine data represent some of the most commercially valuable enterprise software opportunities in the region. For financial services firms, the growth of health insurance penetration, the expansion of medical tourism and the capital requirements of life sciences manufacturing investment all create new product and advisory opportunities.
The UAE’s bet on life sciences is not purely a healthcare play. It is an economic diversification strategy that threads through real estate, technology, finance, education and tourism simultaneously. The $30 billion GCC pharma market is the baseline from which that broader economic opportunity grows. For businesses across the UAE that are thinking about where the next decade of growth is concentrated, life sciences deserves to be on the list alongside AI, real estate and financial services. The infrastructure is being built. The regulatory framework is being put in place. The institutional commitment at the highest levels of government is visible and consistent. The opportunity is real and it is now.
“The UAE is not just building healthcare infrastructure. It is building a life sciences economy that connects precision medicine, longevity wellness, pharmaceutical manufacturing, AI diagnostics and medical tourism into a single integrated proposition designed to attract patients, researchers, investors and residents from around the world.”
— PureHealth, UAE Life Sciences Sector Review 2026 (purehealth.ae, June 2026)
